{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:04:56Z","timestamp":1786125896823,"version":"build-2736575974"},"reference-count":25,"publisher":"Mattioli1885","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Introduction: The interleukin (IL)-4\/IL-13 signaling pathway is central to the pathogenesis of atopic dermatitis (AD). Stapokibart (CM310) is a novel humanized monoclonal antibody targeting the IL-4 receptor alpha (IL-4R\u03b1) subunit. Objective: To summarize current evidence on the mechanism of action, clinical efficacy, safety, and therapeutic potential of stapokibart for moderate-to-severe AD. Methods: A narrative review was conducted based on a targeted search of PubMed\/MEDLINE and ClinicalTrials.gov covering literature published from January 2015 to January 2026. \u00a0Results:\u00a0 Stapokibart binds IL-4R\u03b1 with high affinity (KD = 0.25 nM), inhibiting downstream IL-4 and IL-13 signaling. In a phase 3 trial (N=500), stapokibart 300 mg every two weeks demonstrated significant improvements at Week 16, with 66.9% achieving EASI-75 (vs. 25.8% placebo) and 44.2% achieving IGA 0\/1 (vs. 16.1% placebo; P&lt;0.0001). Among responders, 92.5% maintained EASI-75 through Week 52. The treatment was generally well tolerated, with upper respiratory tract infections and injection-site reactions being the most common adverse events. Conjunctivitis occurred at low rates (5.0\u20135.9%). Conclusions: Stapokibart shows robust efficacy and a favorable safety profile in adults with moderate-to-severe AD, including sustained long-term responses and low conjunctivitis rates. While early data are encouraging, all comparisons with existing IL-4\/IL-13 inhibitors are indirect, and further global phase 3 studies and real-world evidence are needed to define its role within treatment algorithms.<\/jats:p>","DOI":"10.5826\/dpc.1603a7230","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:08:23Z","timestamp":1785510503000},"page":"7230","source":"Crossref","is-referenced-by-count":0,"title":["Stapokibart (CM310) in Atopic Dermatitis: A Narrative Review of a Next-Generation IL-4R\u03b1 Antagonist"],"prefix":"10.5826","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5880-9765","authenticated-orcid":false,"given":"Esmeraldito","family":"Ferreira","sequence":"first","affiliation":[{"name":"1 Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China. 2 The First School of Clinical Medicine, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"first","affiliation":[{"name":"1 Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China. 2 The First School of Clinical Medicine, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"Chen","sequence":"first","affiliation":[{"name":"1 Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China. 2 The First School of Clinical Medicine, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27750","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"10.5826\/dpc.1603a7230_ref1","doi-asserted-by":"crossref","unstructured":"Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54-62. DOI:10.1111\/all.13954","DOI":"10.1111\/all.13954"},{"key":"10.5826\/dpc.1603a7230_ref2","doi-asserted-by":"crossref","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360. DOI:10.1016\/S0140-6736(20)31286-1","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"10.5826\/dpc.1603a7230_ref3","doi-asserted-by":"crossref","unstructured":"Davis DM, Waldman A, Jacob S, et al. Diagnosis, comorbidity, and psychosocial impact of atopic dermatitis. Semin Cutan Med Surg. 2017;36(3):95-99. DOI:10.12788\/j.sder.2017.028","DOI":"10.12788\/j.sder.2017.028"},{"key":"10.5826\/dpc.1603a7230_ref4","doi-asserted-by":"crossref","unstructured":"Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144-151. DOI:10.1016\/j.anai.2019.04.020","DOI":"10.1016\/j.anai.2019.04.020"},{"key":"10.5826\/dpc.1603a7230_ref5","doi-asserted-by":"crossref","unstructured":"Megna M, Napolitano M, Patruno C, et al. Systemic Treatment of Adult Atopic Dermatitis: A Review. Dermatol Ther (Heidelb). 2017;7(1):1-23. DOI:10.1007\/s13555-016-0170-1","DOI":"10.1007\/s13555-016-0170-1"},{"key":"10.5826\/dpc.1603a7230_ref6","doi-asserted-by":"crossref","unstructured":"Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133(2):429-438. DOI:10.1016\/j.jaci.2013.07.049","DOI":"10.1016\/j.jaci.2013.07.049"},{"key":"10.5826\/dpc.1603a7230_ref7","doi-asserted-by":"crossref","unstructured":"Fujii M. Current Understanding of Pathophysiological Mechanisms of Atopic Dermatitis: Interactions among Skin Barrier Dysfunction, Immune Abnormalities and Pruritus. Biol Pharm Bull. 2020;43(1):12-19. DOI:10.1248\/bpb.b19-00088","DOI":"10.1248\/bpb.b19-00088"},{"key":"10.5826\/dpc.1603a7230_ref8","doi-asserted-by":"crossref","unstructured":"Bitton A, Avlas S, Reichman H, et al. A key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis. Sci Immunol. 2020;5(44):eaaw2938. DOI:10.1126\/sciimmunol.aaw2938","DOI":"10.1126\/sciimmunol.aaw2938"},{"key":"10.5826\/dpc.1603a7230_ref9","doi-asserted-by":"crossref","unstructured":"Huang IH, Chung WH, Wu PC, et al. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review. Front Immunol. 2022;13:1068260. Published 2022 Dec 8. DOI:10.3389\/fimmu.2022.1068260","DOI":"10.3389\/fimmu.2022.1068260"},{"key":"10.5826\/dpc.1603a7230_ref10","doi-asserted-by":"crossref","unstructured":"Sroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int J Mol Sci. 2021;22(8):4130. Published 2021 Apr 16. DOI:10.3390\/ijms22084130","DOI":"10.3390\/ijms22084130"},{"key":"10.5826\/dpc.1603a7230_ref11","doi-asserted-by":"crossref","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303. DOI:10.1016\/S0140-6736(17)31191-1","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"10.5826\/dpc.1603a7230_ref12","unstructured":"D'Ippolito D, Pisano M. Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis. P T. 2018;43(9):532-535. PMID: 30186024"},{"key":"10.5826\/dpc.1603a7230_ref13","doi-asserted-by":"crossref","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-2348. DOI:10.1056\/NEJMoa1610020","DOI":"10.1056\/NEJMoa1610020"},{"key":"10.5826\/dpc.1603a7230_ref14","doi-asserted-by":"crossref","unstructured":"Fachler T, Shreberk-Hassidim R, Molho-Pessach V. Dupilumab-induced ocular surface disease: A systematic review. J Am Acad Dermatol. 2022;86(2):486-487. DOI:10.1016\/j.jaad.2021.09.029","DOI":"10.1016\/j.jaad.2021.09.029"},{"key":"10.5826\/dpc.1603a7230_ref15","doi-asserted-by":"crossref","unstructured":"Shirley M. Stapokibart: First Approval. Drugs. 2025;85(5):715-720. DOI:10.1007\/s40265-025-02151-7","DOI":"10.1007\/s40265-025-02151-7"},{"key":"10.5826\/dpc.1603a7230_ref16","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhang W, Xu Y, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis. Adv Ther. 2024;41(7):2953-2965. DOI:10.1007\/s12325-024-02887-w","DOI":"10.1007\/s12325-024-02887-w"},{"key":"10.5826\/dpc.1603a7230_ref17","doi-asserted-by":"crossref","unstructured":"Crescioli S, Kaplon H, Wang L, Visweswaraiah J, Kapoor V, Reichert JM. Antibodies to watch in 2025. MAbs. 2025;17(1):2443538. DOI:10.1080\/19420862.2024.2443538","DOI":"10.1080\/19420862.2024.2443538"},{"key":"10.5826\/dpc.1603a7230_ref18","doi-asserted-by":"crossref","unstructured":"Liu W, Zhao Y, He Y, et al. Stapokibart (CM310) targets IL-4R\u03b1 for the treatment of type 2 inflammation. iScience. 2024;27(9):110721. Published 2024 Aug 13. DOI:10.1016\/j.isci.2024.110721","DOI":"10.1016\/j.isci.2024.110721"},{"key":"10.5826\/dpc.1603a7230_ref19","doi-asserted-by":"crossref","unstructured":"Liu W, Zhao Y, He Y et al. 743 Stapokibart (CM310), with different epitope than dupilumab, shows potent inhibition on type 2 inflammation. Journal of Investigative Dermatology 2024; 144: S130. DOI: 10.1016\/j.jid.2024.06.759","DOI":"10.1016\/j.jid.2024.06.759"},{"key":"10.5826\/dpc.1603a7230_ref20","doi-asserted-by":"crossref","unstructured":"Zhao Y, Zhang J, Yang B, et al. Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial. Chin Med J (Engl). 2024;137(2):200-208. DOI:10.1097\/CM9.0000000000002747","DOI":"10.1097\/CM9.0000000000002747"},{"key":"10.5826\/dpc.1603a7230_ref21","doi-asserted-by":"crossref","unstructured":"Zhao Y, Zhang L, Zhang J; CM310AD005 Study Investigators. Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2024;91(5):984-986. DOI:10.1016\/j.jaad.2024.07.1447","DOI":"10.1016\/j.jaad.2024.07.1447"},{"key":"10.5826\/dpc.1603a7230_ref22","doi-asserted-by":"crossref","unstructured":"Zhao Y, Zhang L, Wu L, et al. Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial. Allergy. 2025;80(5):1348-1357. DOI:10.1111\/all.16368","DOI":"10.1111\/all.16368"},{"key":"10.5826\/dpc.1603a7230_ref23","doi-asserted-by":"crossref","unstructured":"Zhao Y, Zhang L, Wu L, et al. Efficacy and Safety of Stapokibart in Adults With Moderate-to-Severe Atopic Dermatitis With and Without Type 2 Comorbidities: A Post Hoc Analysis of a Phase 3 Trial. Clin Transl Allergy. 2025;15(11):e70121. DOI:10.1002\/clt2.70121","DOI":"10.1002\/clt2.70121"},{"key":"10.5826\/dpc.1603a7230_ref24","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740-748. DOI:10.1093\/bjd\/ljad022","DOI":"10.1093\/bjd\/ljad022"},{"key":"10.5826\/dpc.1603a7230_ref25","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437-449. DOI:10.1111\/bjd.19574","DOI":"10.1111\/bjd.19574"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/7230\/3955","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/7230\/3955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:20:49Z","timestamp":1786123249000},"score":1,"resource":{"primary":{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/view\/7230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1603a7230","relation":{"has-manifestation":[{"id-type":"other","id":"1-84-7230-g3955","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.1603a%a","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1"}}